留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

P53-MDM2界面的肽类及拟肽类抑制剂的研究进展

李翔,  邹燕,  吴茂诚,  黄婷,  胡宏岗,  吴秋业

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(6): 494-497,512
李翔, 邹燕, 吴茂诚, 黄婷, 胡宏岗, 吴秋业. P53-MDM2界面的肽类及拟肽类抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
引用本文: 李翔, 邹燕, 吴茂诚, 黄婷, 胡宏岗, 吴秋业. P53-MDM2界面的肽类及拟肽类抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
shu
LI Xiang, ZOU Yan, WU Maocheng, HUANG Ting, HU Honggang, WU Qiuye. Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
Citation: LI Xiang, ZOU Yan, WU Maocheng, HUANG Ting, HU Honggang, WU Qiuye. Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
shu

P53-MDM2界面的肽类及拟肽类抑制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.004

  • 第二军医大学药学院有机化学教研室, 上海 200433

Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface

  • Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 当前,肿瘤疾病以日益增高的发病率越来越受到人们的重视。抑制P53-MDM2的相互作用已经成为治疗癌症药物设计的重要靶标,通过各种药物筛选手段,研究人员发现了许多肽类及小分子抑制剂。综述近年来国内外关于肽类及拟肽类的P53-MDM2抑制剂的研究进展。
    Abstract: Tumor diseases have attracted great attention of the society because of the increasing morbidity in recent years. To inhibit the P53-MDM2 interaction has become an important target for design of cancer drug, and a lot of peptide and small molecule inhibitors have been found with various kinds of drug screening and research tools. This paper summarized the recent progress of the peptide and peptidomimetic inhibitors of P53-MDM2 at home and abroad lately.
  • [1] Oliner JD, Kinzler KW, Meltzer PS, et al. Amplication of a gene encoding a p53-associated protein in human sarcomas[J]. Nature, 1992, 358: 80-83.
    [2] Levine AJ. P53, the cellular gate keeper for growth and division[J]. Cell, 1997, 88(3): 323-331.
    [3] Bert V, David L, Arnold JL. Surfing the p53 network[J]. Nature, 408: 307-310.
    [4] Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53[J]. Nature, 1993, 362: 857-860.
    [5] Pickskey SM, Lane DP. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53[J]. BioEssays, 1993, 15: 689-690.
    [6] Raymond EM, Melanie C, Tina ND, et al. Direct inhibition of the NOTCH transcription factor complex[J]. Nature, 2009, 462(7270): 182-188.
    [7] Wu X, Bayle JH, Olson D, et al. The P53-mdm-2 autoregulatory feedback loop[J]. Genes Devel, 1993, 7(7a): 1126-1132.
    [8] Almerico AM, Tutone M, Pantano L, et al. Molecular dynamics studies on Mdm2 complexes: an analysis of the inhibitor influence[J]. Biochem Biophys Res Commun, 2012, 424(2): 341-347.
    [9] Meng W, Brigance RP, Chao HJ,et al. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxa mides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors[J]. J Med Chem, 2010, 53(15): 5620-5628.
    [10] Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the P53 pathway by small-molecule antagonists of MDM2[J]. Science, 2004, 303(5659): 844-848.
    [11] Wang B, Fang L, Zhao H, et al. MDM2 inhibitor nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells[J]. Acta Biochim Biophys Sin (Shanghai), 2012, 44(8): 685-691.
    [12] Warner WA, Sanchez R, Dawoodian A, et al. Identification of FDA-approved drugs that computationally bind to MDM2[J]. Chem Biol Drug Des, 2012, 80(4): 631-637.
    [13] Zhuang C, Miao Z, Zhu L, et al. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the P53-MDM2 protein-protein interaction[J]. Eur J Med Chem, 2011, 46(11): 5654-5661.
    [14] Grasberger BL, Lu T, Schubert C, et al. Discovery and cocrystalstructure of benzodiazepinedione MDM2 antagonists that activate P53 in cells. J Med Chem, 2005, 48(4): 909-912.
    [15] Mohammad RM, Wu J, Azmi AS, et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals[J]. Mol Cancer, 2009, 8: 115.
    [16] Andrea GC. Protein-protein interfaces: mimics and inhibitors[J]. Curr Opin Chem Biol, 2001, 5:654-659.
    [17] Arkin MR and Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream[J]. Nat Rev Drug Discov, 2004, 3(4): 301-317.
    [18] Pazgier M, Liu M, Zou G, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX[J]. Proc Natl Acad Sci(USA), 2009, 106(12): 4665-4670.
    [19] Chang YS, Graves B, Guerlavais V, et al. Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy[J]. Proc Natl Acad Sci USA, 2013, 110(36): E3445-E3454.
    [20] Li C, Pazgier M, Liu M, et al. Apamin as a template for structure-based rational design of potent peptide activators of p53[J]. Angew Chem Int Ed Engl, 2009, 48(46): 8712-8715.
    [21] Li C, Zhan C, Zhao L, et al. Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction[J]. Bioorg Med Chem, 2013, 21(14): 4045-4050.
    [22] Hu Y, Li X, Sebti SM, et al. Design and synthesis of peptides: a new class of peptide mimics[J]. Bioorg Med Chem Lett, 2011, 21(5): 1469-1471.
    [23] Noguchi T, Oishi S, Honda K, et al. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors[J]. Bioorg Med Chem Lett, 2013, 23(13): 3802-3805.
    [24] Duncan SJ, Gruschow S, Williams DH, et al. Isolation and structure elucidation of chlorofusin, a novel P53-MDM2 antagonist from a Fusarium sp[J]. J Am Chem Soc, 2001, 123: 554-560.
    [25] Lee SY and Boger DL. Synthesis of the chlorofusin cyclic peptide[J]. Tetrahedron, 2009, 65(16): 3281-3284.
    [26] Sakurai K and Kahne D. Design and synthesis of functionalized trisaccharides as P53-peptide mimics[J]. Tetrahedron Lett, 2010, 51(29): 3724-3727.
    [27] Phan J, Li Z, Kasprzak A, et al. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX[J]. J Biol Chem, 2010, 285(3): 2174-2183.
    [28] Liu M, Pazgier M, Li C, et al. A left-handed solution to peptide inhibition of the P53-MDM2 interaction[J]. Angew Chem Int Ed Engl, 2010, 49(21): 3649-3652.
    [29] Li C, Pazgier M, Li J, et al. Limitations of peptide retro-inverso isomerization in molecular mimicry[J]. J Biol Chem, 2010, 285(25): 19572-19581.
    [30] Harker EA and Schepartz A. Cell-permeable beta-peptide inhibitors of p53/hDM2 complexation[J]. Chembiochem, 2009, 10(6): 990-993.
    [31] Hintersteiner M, Kimmerlin T, Garavel G, et al. A highly potent and cellularly active beta-peptidic inhibitor of the p53/hDM2 interaction[J]. Chembiochem, 2009, 10(6): 994-998.
    [32] Yamada S, Kanno H and Kawahara N. Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53[J]. J Neurooncol, 2012, 109(1): 7-14.
    [33] Li C, Shen J, Wei X, et al. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy[J]. J Drug Target, 2012, 20(3): 264-271.
    [34] Jeong WJ, Lee MS and Lim YB. Helix stabilized, thermostable, and protease-resistant self-assembled peptide nanostructures as potential inhibitors of protein-protein interactions[J]. Biomacromolecules, 2013, 14(8): 2684-2689.
    [35] Muppidi A, Wang Z, Li X, et al. Achieving cell penetration with distance-matching cysteine cross-linkers: a facile route to cell-permeable peptide dual inhibitors of Mdm2/Mdmx[J]. Chem Commun (Camb), 2011, 47(33): 9396-9398.
    [36] Muppidi A, Li X, Chen J, et al. Conjugation of spermine enhances cellular uptake of the stapled peptide-based inhibitors of p53-Mdm2 interaction[J]. Bioorg Med Chem Lett, 2011, 21(24): 7412-7415.
    [37] Madden MM, Muppidi A, Li Z, et al. Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition[J]. Bioorg Med Chem Lett, 2011, 21(5): 1472-1476.
  • [1] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [2] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
    [3] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [4] 张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳.  基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 445-450. doi: 10.12206/j.issn.2097-2024.202403057
    [5] 刘汝雄, 杨万镇, 涂杰, 盛春泉.  铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3537
  • HTML全文浏览量:  310
  • PDF下载量:  350
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-11-25
  • 修回日期:  2014-03-31

P53-MDM2界面的肽类及拟肽类抑制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.004
  • 第二军医大学药学院有机化学教研室, 上海 200433
  • 收稿日期: 2013-11-25
  • 修回日期: 2014-03-31

摘要: 当前,肿瘤疾病以日益增高的发病率越来越受到人们的重视。抑制P53-MDM2的相互作用已经成为治疗癌症药物设计的重要靶标,通过各种药物筛选手段,研究人员发现了许多肽类及小分子抑制剂。综述近年来国内外关于肽类及拟肽类的P53-MDM2抑制剂的研究进展。

English Abstract

李翔, 邹燕, 吴茂诚, 黄婷, 胡宏岗, 吴秋业. P53-MDM2界面的肽类及拟肽类抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
引用本文: 李翔, 邹燕, 吴茂诚, 黄婷, 胡宏岗, 吴秋业. P53-MDM2界面的肽类及拟肽类抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
shu
LI Xiang, ZOU Yan, WU Maocheng, HUANG Ting, HU Honggang, WU Qiuye. Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
Citation: LI Xiang, ZOU Yan, WU Maocheng, HUANG Ting, HU Honggang, WU Qiuye. Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 494-497,512. doi: 10.3969/j.issn.1006-0111.2015.06.004
shu

    全文HTML

参考文献 (37)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计